Overview and Scope
Renal biomarker refers to proteins, lipids, genes, metabolites, proteomic patterns, or cells that are found on a urinalysis that is employed to determine the glomerular filtration rate of the kidney, a drop in which indicates kidney damage. The renal biomarkers are used to estimate the nature and severity of kidney injury.
Sizing and Forecast
The renal biomarkers market size has grown strongly in recent years. It will grow from <b>$1.17 billion in 2023 to $1.27 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. </b> The growth in the historic period can be attributed to increasing prevalence of kidney diseases, advances in medical diagnostics, aging population, growing awareness of early disease detection, adoption of point-of-care testing, rise in chronic diseases..
The renal biomarkers market size is expected to see strong growth in the next few years. It will grow to <b>$1.74 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. </b> The growth in the forecast period can be attributed to personalized medicine and targeted therapies, integration of biomarker testing into routine clinical practice, emerging markets in asia and latin america, non-invasive biomarker testing methods, continuous monitoring with wearable devices.. Major trends in the forecast period include multiplex biomarker panels for comprehensive disease profiling, ai and machine learning for biomarker discovery, biomarker-based companion diagnostics, poc biomarker testing in home healthcare settings, biomarkers for early detection and prevention..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Segmentation & Regional Insights
The renal biomarkers market covered in this report is segmented –
1) By Biomarker Type: Functional Biomarker, Up Regulated Protein, Other Biomarker Types
2) By Diagnostic Technique: Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS)
3) By Application: Diagnosis And Disease Progression Monitoring, Research Homecare
4) By End User: Hospitals, Diagnostic Laboratories, Other End Users
<b>North America</b> was the largest region in the renal biomarkers market in 2023. <b>Asia-Pacific</b> is expected to be the fastest-growing region during the forecast period. The regions covered in the renal biomarkers market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7711&type=smp
Major Driver Impacting Market Growth
The rise in geriatric and paediatric renal patients is expected to propel the growth of the renal biomarkers market going forward. Geriatric renal patients refer to the elderly patients aged above 70 years with advanced chronic kidney disease (CKD). However, paediatric renal patients refer to the patients who are commonly diagnosed with renal disorder during childhood and young adulthood. Renal biomarkers help to evaluate the severity of renal injury in geriatric and paediatric renal patients. For instance, in March 2021, according to the data published by the Centers for Disease Control and Prevention, a US-based government administrative agency, nearly 37 million adults in the US have chronic renal disease and it is more prevalent in adults 65 years of age and older (38%). Therefore, the rise in geriatric and paediatric renal patients is driving the growth of the renal biomarkers market.
Key Industry Players
Major companies operating in the renal biomarkers market include <b> Abbott Laboratories, BioPorto Diagnostics A/S, Roche Holding AG, Thermo Fisher Scientific, bioMérieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter Inc., Astute Medical Inc., Nexelis Company, Sphingotec GmbH, Bio-Rad Laboratories India Pvt. Ltd., Enzo Biochem Inc., PerkinElmer Inc., Novartis AG, Eli Lilly and Company, Alere Inc., AstraZeneca plc, Bio-Techne Corp., DiaSorin S.p.A., EKF Diagnostics Holdings plc, Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Merck KGaA, Myriad RBM Inc., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, R&D Systems Inc., Roche Diagnostics International Ltd ., Sekisui Chemical Co. Ltd., Sysmex Corporation, Tosoh Bioscience Inc. </b>
The renal biomarkers market report table of contents includes:
1. Executive Summary
2.Renal Biomarkers Market Characteristics
3Renal Biomarkers. Market Trends And Strategies
4. Renal Biomarkers market analysis
5.Renal Biomarkers Market Size And Growth
6.Renal Biomarkers Segmentation
7.Renal Biomarkers Regional And Country Analysis
.
.
.
27.Renal Biomarkers Competitive Landscape And Company Profiles
28.Renal Biomarkers Key Mergers And Acquisitions
29.Renal Biomarkers Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
